Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
B-Lymphocytes
Lymphoma, B-Cell
T-Lymphocytes
Antigens, CD19
Receptors, Antigen, T-Cell
Hematopoietic Stem Cell Transplantation
Humans
Neoplasm Recurrence, Local
Immunotherapy, Adoptive
Research Articles
3. Good health
DOI:
10.1158/2326-6066.cir-22-0910
Publication Date:
2023-05-31T20:38:10Z
AUTHORS (12)
ABSTRACT
Abstract Despite the remarkable success of autologous chimeric antigen receptor (CAR) T cells, some patients relapse due to tumor escape and low or uneven expression, among other mechanisms. Therapeutic options after are limited, emphasizing need optimize current approaches. In addition, there is a develop allogeneic “off-the-shelf” therapies from healthy donors that readily available at time treatment decision can overcome limitations To address both challenges simultaneously, we generated CD20xCD22 dual CAR cell. Herein, demonstrate CD20x22 cells display robust, sustained dose-dependent activity in vitro vivo, while efficiently targeting primary B-cell non–Hodgkin lymphoma (B-NHL) samples with heterogeneous levels CD22 CD20. Altogether, provide preclinical proof-of-concept data for an cell mechanisms resistance T-cell B-NHL, providing potential alternative CD19 targeting.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (61)
CITATIONS (6)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....